EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPETITORS
BRANDS
* Login for a full stack data experience
DATE
APR 2021
TABLES
210
PAGES
261
EDITION
16
PRICE
USD $5600
HIGHLIGHTS
SELECT PLAYERS
Allergan Plc.; AMAG Pharmaceuticals Inc.; American Regent Inc.; Luitpold Pharmaceuticals; Pharmacosmos A/S; Sanofi US; Vifor Fresenius Medical Care Renal Pharma; Vifor Pharma Ltd.
SEGMENTS
» Product Type (Ferric Carboxyl Maltose, Iron Sucrose, Other Product Types) » Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Iron Deficiency Anemia (IDA) - An Overview |
Recent Market Activity |
Intravenous (IV) Iron Drugs Market - A Quick Primer |
US and Europe Dominate IV Iron Market |
Asia-Pacific - The Fastest Growing Market |
Leading Intravenous Iron Drugs Globally |
Leading IV Iron Drugs Available in the Market |
Leading Intravenous Iron Drugs: In a Nutshell |
Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally |
Venofer® - Looses Ground to Ferinject |
Feraheme Obtains Broader Label Approval |
Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA |
Gluconate (Ferrlecit® and Nulecit) |
Dextran |
Global Market Leaders |
2. FOCUS ON SELECT PLAYERS |
Allergan Plc. (Ireland) |
AMAG Pharmaceuticals, Inc. (USA) |
Daiichi Sankyo, Inc. (USA) |
Luitpold Pharmaceuticals, Inc. (USA) |
American Regent, Inc. (USA) |
Pharmacosmos A/S (Denmark) |
Sanofi US (USA) |
Vifor Pharma Ltd. (Switzerland) |
Vifor Fresenius Medical Care Renal Pharma (Switzerland) |
3. MARKET TRENDS & DRIVERS |
Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Intravenous (IV) Iron Drugs |
ESRD Prevalence Statistics: An Opportunity Indicator |
Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market |
Dialysis Patients - A Major Market for Intravenous Iron Supplements |
Ageing Population Drives Demand for IV Iron Drugs |
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs |
Comparison of Ferrous Salts with IV Iron Therapy |
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs |
Anemia in Heart Failure - A Market with Huge Potential |
Chemotherapy Induced Anemia to Promote IV Iron Supplements |
Correction of IDA in Pregnancy Signals Opportunities |
Women’s Health - A Key Growth Opportunity |
Perioperative and Postoperative Anemia - A Niche Market Beckons |
Adverse Reactions of IV Iron Preparations Raise Concerns |
Dosing Limitations Plague IV Iron Market |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Ferric Carboxyl Maltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Ferric Carboxyl Maltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Ferric Carboxyl Maltose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Iron Sucrose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
USA Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Canada Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Japan Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
China Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
France Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Germany Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Italy Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
UK Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
SPAIN |
Spain Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Spain Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
RUSSIA |
Russia Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Russia Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Rest of Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
AUSTRALIA |
Australia Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Australia Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
INDIA |
India Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
India Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
SOUTH KOREA |
South Korea Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
South Korea Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Rest of Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
LATIN AMERICA |
Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 |
Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
ARGENTINA |
Argentina Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Argentina Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
BRAZIL |
Brazil Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Brazil Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
MEXICO |
Mexico Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Mexico Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
REST OF LATIN AMERICA |
Rest of Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Rest of Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
MIDDLE EAST |
Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 |
Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
IRAN |
Iran Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Iran Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
ISRAEL |
Israel Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Israel Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
SAUDI ARABIA |
Saudi Arabia Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Saudi Arabia Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
UNITED ARAB EMIRATES |
UAE Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
UAE Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
REST OF MIDDLE EAST |
Rest of Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Rest of Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
AFRICA |
Africa Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
Africa Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 21 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com